{"entity":{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","aka":[],"tldr":"Lung cancer trialist behind KEYNOTE-010 and the ADAURA adjuvant osimertinib trial.","summary":"Roy Herbst (Yale Cancer Center) led KEYNOTE-010, the trial that established pembrolizumab for previously treated PD-L1-positive NSCLC, and was co-principal investigator of ADAURA, which showed adjuvant osimertinib dramatically cuts recurrence and improves survival in resected EGFR-mutant lung cancer. He co-led the Lung-MAP master protocol and the early atezolizumab biomarker work. His current focus is adjuvant and neoadjuvant targeted therapy.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Roy_S._Herbst","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herbst%20RS%5BAuthor%5D%20lung%20pembrolizumab%20OR%20osimertinib"}],"tags":["lung","immunotherapy","adjuvant"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["pd1","egfr"],"drugs":["pembrolizumab","osimertinib","atezolizumab"],"companies":[],"institutions":["yale-cancer-center","dartmouth-cancer-center"],"pathways":[],"terms":[],"trials":["adaura"],"people":[],"bottlenecks":[],"keyPapers":["paper-adaura-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director and Chief of Medical Oncology, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["Lung cancer immunotherapy","Adjuvant targeted therapy","Early drug development","Biomarkers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herbst%20RS%5BAuthor%5D%20lung%20pembrolizumab%20OR%20osimertinib"}],"papers":[{"title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010)","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(15)01281-7"},{"title":"Adjuvant osimertinib for resected EGFR-mutated NSCLC: overall survival (ADAURA)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2304594"},{"title":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027071","doi":"10.1056/NEJMoa2027071"}]},"route":"/people/roy-herbst/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"dartmouth-cancer-center","kind":"institution","name":"Dartmouth Cancer Center","route":"/institutions/dartmouth-cancer-center/"},{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/"}],"trial":[{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/"},{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/"}],"paper":[{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/"},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/"},{"id":"paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020","kind":"paper","name":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","route":"/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/"},{"id":"paper-keynote-010-lancet-2016","kind":"paper","name":"KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer","route":"/key-papers/paper-keynote-010-lancet-2016/"}],"term":[{"id":"master-protocol","kind":"term","name":"Master protocol (platform, basket and umbrella trials)","route":"/terms/master-protocol/"}]}}